Companies

Skin Analytics won the 2018 UKBAA Best AI Investment, 2018 Advance Queensland Ignite Grant, and have received several other awards and grants. They are expanding further, into public and private healthcare markets, in the UK, Australia, and New Zealand.

The company has entered into agreements in primary care, and has commercial contracts with private medical insurers and providers.

Skin Analytics raised funding to finalise the first prospective clinical study in applying AI to dermatology, secure regulatory approvals, and develop the high-calibre team to deploy the technology into patient care pathways.

LiveSmart participated in the RYSE DigitalHealth.London Investment Programme to gain the further technological validation of their product through the panel of reviewers and to benefit from RYSE’s experienced network.

The company's development focus is via commercial partnerships with health insurers, other intermediaries, in additional to a direct to consumer model. Their partnership with AXA PPP has provided LiveSmart a mark of pre-approval and global access to over 100 million customers.

LiveSmart raised funding to expand sales into other geographical jurisdictions, secure additional long-term partnerships internationally in the insurance market, and to further improve their product.

Data can be added to a library from thousands of different sources, including social, financial, and healthcare. The user owns the library and keeps it on their choice of secure cloud storage. The user can share data with 3rd parties directly from their device, enabling complete control over privacy.

Based in the UK, digi.me has grown to over 60 people with offices in France, Iceland, Australia, and the US.

Digi.me raised £18 million funding in this round. They have a fully developed product that is currently being used by dozens of market partners including Facebook.

Knokcare’s product, Panacea, aims to be the reference white label provider for virtual consultations. Panacea incorporates clinical support, for both patient and clinician (integrated web and mobile apps), which integrate seamlessly into the existing patient journey and connect with enterprise systems.

The company is active, in both Europe and the Americas, and has entered into commercial contracts with private medical insurers and corporate providers.

Knokcare raised funding in this round to further develop Panacea for use in the European market.

Log my Care’s product enables care planning from a smart management system and saves a carer's time with an easy to use mobile app. It runs on most mobile devices and is designed to allow carers to easily record and coordinate care on the go.

The company has experienced rapid organic growth in the UK and has entered into agreements with several care home groups.

Log my Care raised £600k funding in this round to further develop their freemium product for use in the European market.

Firza’s product allows primary healthcare practices to adjust to changes in demand and to respond with a solution that integrates into the team’s existing workflow. They have utilised professional skills, experience, and technology to validate opportunities for cost efficiencies and value-based healthcare.

The company has demonstrated significant revenue growth and has entered into agreements with multinational healthcare providers.

Firza raised funding in this round to further develop their Robotic Process Automation, Artificial Intelligence, and scalability of their product.

MediShout’s product allows healthcare providers to prioritise problems and predictive software analytics prevent equipment issues! The company launched their application with healthcare providers and works with suppliers to integrate communication in the clinical setting.

The company is active in NHS hospitals, and clinics, and allows healthcare providers to instantly report any issues encountered. Users simply select their location, describe their problem, add a photo, and press Shout!

MediShout raised seed funding, was awarded an Innovate UK grant, and is a member of the NHS Clinical Entrepreneur programme.

Tinnitus is a growing problem globally and the treatment landscape is changing in the UK – new guidelines by National Institute for Clinical Excellence (NICE) and Royal College of General Practitioners (RCGP) recommend digital tinnitus-related cognitive behavioural therapy (CBT) as first line treatment.

Oto’s tinnitus relief therapy product is live on the App Store and Google Play.

Oto is raising £850k in this round and is a member of the NHS Clinical Entrepreneur programme.

The company is the only B2B2C marketplace in this space, offering a quick and seamless prescription experience for patients and pharmacies. With this unique model, they can offer a faster, more scalable service than online pharmacies without incurring any of the logistics and admin costs.

Healthera’s pharmacy’s NHS prescription delivery product is live on the App Store and Google Play, NHS App Library with 4.7+ star ratings.

Healthera is raising £3m in this round and, since 2018, has scaled to over 1,100 pharmacies and handled over 2 million prescription items.

Vigilent Labs has developed a comprehensive point-of-care “Lab In Your Hand” with near real-time global, regional, and local tracking of disease. The company provides lateral flow immunoassays for point of care tests, a unique digital health credential (v.PASS) and Web-portal solution (VLMS) tied into open architecture databases, and displays for managing health information at an organisational level.

The company has substantial experience in the development of health surveillance technologies and medical devices in partnership with the U.S. military, governments and public providers.

Vigilent Labs is raising seed funding to develop a unique set of capabilities well suited for end-to-end response to COVID-19 and is building out its pipeline of detection & diagnostics to expand its platform.